Unlike heparin, recombinant hirudin does not need antithrombin as a cofactor, and hirudin also inhibits clot-bound thrombin. Such blocking of all thrombin activity should lead to the interruption of ...

Current Antithrombin Therapies in Patients With ACS Undergoing an Invasive Approach Unfractionated heparin (UFH) was discovered in 1916 by Jay McLean, then a second-year medical student working ...

Bivalirudin has several notable mechanistic advantages compared with unfractionated heparin, including activity against clot-bound thrombin, inhibition of thrombin-induced platelet activation, short ...

In contrast to the use of heparin, antithrombin has not been shown to increase the risk of bleeding. However, antithrombin treatment has so far not been investigated in randomized studies in women ...

Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.

Heparin-poloxamer increased the stability and bioavailability of rhFGF20. HP-rhFGF20 attenuated neurobehavioral deficits and infarct volume in ischemic stroke rats. HP-rhFGF20 inhibited neuronal cell ...

Antithrombin deficiency is associated with increased risk of venous thrombosis. In certain families, this condition is caused by pathogenic polymerization of mutated antithrombin in the blood. To ...

Binding between FGF-2 and heparin had strong slip bond characteristics as demonstrated by a decrease of lifetime with tensile force on the complex. Unbinding forces between FGF-2 and heparin were ...